Reprogenesis

Registration country: 
United States
ISIC Code: 
2100
Company type: 
A public company focused on regenerative medicine.
Overview: 
Company developing in vivo tissue augmentation/repair products. Reprogenesis merged in July 2000 with Creative Biomolecules and Ontogeny to form Curis, a public company focused on regenerative medicine. Curis is developing products that are designed to recreate the conditions that support the growth of cells and tissue.